A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients’ Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients’ Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 8, Pages 1879
Publisher
MDPI AG
Online
2022-04-09
DOI
10.3390/cancers14081879
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
- (2021) Javier Martínez-Trufero et al. Cancers
- Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group
- (2021) Emanuela Palmerini et al. Cancers
- Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin
- (2021) Chiara Fabbroni et al. Cancers
- Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG)
- (2020) Leopold Hentschel et al. BMJ Open
- The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of a Nationwide Observational Study (PROSa)
- (2020) Martin Eichler et al. Cancers
- Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
- (2020) Nadia Hindi et al. Cancers
- Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
- (2019) Shreyaskumar Patel et al. CANCER
- Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2018) P G Casali et al. ANNALS OF ONCOLOGY
- Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study
- (2018) Charles A. Stiller et al. Cancer Epidemiology
- Symptom Burden in Advanced Soft-Tissue Sarcoma
- (2017) Nicholas Gough et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
- (2016) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group
- (2015) Axel Le Cesne et al. EUROPEAN JOURNAL OF CANCER
- Epidemiology And Treatment Of Soft Tissue Sarcoma In The Eu5
- (2015) D Robinson et al. VALUE IN HEALTH
- Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma
- (2015) Rita De Sanctis et al. Drug Design Development and Therapy
- The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia
- (2014) Line H. Schack et al. ACTA ONCOLOGICA
- Trabectedin for advanced soft tissue sarcomas: a single institution experience
- (2014) Ioannis Gounaris et al. Future Oncology
- Trabectedin in patients with metastatic soft tissue sarcoma
- (2013) Sophie Schur et al. ANTI-CANCER DRUGS
- Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
- (2013) Jean-Yves Blay et al. BMC CANCER
- The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS)
- (2013) F. Ploner et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project
- (2012) C.A. Stiller et al. EUROPEAN JOURNAL OF CANCER
- Rare cancers are not so rare: The rare cancer burden in Europe
- (2011) Gemma Gatta et al. EUROPEAN JOURNAL OF CANCER
- Use of chemotherapy for patients with bone and soft-tissue sarcomas
- (2010) R. WESOLOWSKI et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
- (2010) Thomas Schmitt et al. Marine Drugs
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem
- (2009) Carmen Cuevas et al. NATURAL PRODUCT REPORTS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started